Immunomatics

AI to reduce transplant rejection and save lives

Countdown clock
Exclusive
Friends Invest First
Soft Launch Until Jul 15 @ 10:00 AM ET
--
day
--
hour
--
min
--
sec
INVESTMENT TERMS
Future Equity
 $12M  $10M valuation cap
Early Bird Bonus: The first $100K of investments will be in a SAFE with a $10M valuation cap

Highlights

1
Founded by a stem cell transplant survivor with training in computational biology and AI.
2
Awarded a $207,740 NIH Phase I SBIR grant, non-dilutive capital, & third-party scientific validation
3
Tackling a major unmet need: roughly 1 in 5 kidney transplants fail within five years.
4
AI rejection-risk scoring designed to work with data already collected in pre-transplant workflows.

Team

The problem, too many failed transplants

Behind every failed kidney transplant is a patient forced back to dialysis, a family restarting the transplant waitlist process, and billions in avoidable healthcare costs each year. Immune rejection remains a critical challenge to the long-term success of transplants.

The deeper issue is how donors are selected. Today’s practice counts HLA mismatches and treats them as equally risky, even though evidence shows that some mismatches are well tolerated while others drive rejection. Clinicians lack a reliable tool to tell the difference, so one of the most consequential decisions in medicine is made with a blunt instrument.

A note from our founder

Our Solution

Immunomatics is developing AI software that goes beyond counting mismatches, estimating the relative rejection risk of specific donor-recipient incompatibilities before transplantation. Our platform analyzes donor and patient genetic data to produce a rejection-risk score designed to help transplant teams select safer donors, personalize immunosuppression to each patient’s risk, and monitor for rejection more effectively.

Traditionally, blood stem cell transplants prioritized fully HLA-matched donors. However, advances like post-transplant cyclophosphamide (PTCy) for GVHD prevention have shifted focus toward balancing HLA compatibility with factors such as age, gender, and transplant protocol, making donor selection complex without specialized decision support software.

A rejection-risk score clinicians can act on

The approach is built to fit the clinic, not replace it. Risk analysis uses existing transplant workflow data. No additional testing required.

Traction & Credibility

Beyond the grant, the team is advancing discussions with transplant centers and building the data partnerships needed to validate the model against real-world outcomes. The NIH award is a meaningful external signal: independent reviewers judged both the science and the team worth funding.

Market Opportunity

Reasons to Invest

As with any early-stage healthcare company, this opportunity is subject to scientific, execution, regulatory, and commercialization risks.

Roadmap

Expansion across the U.S. and abroad.

The Team

Built by people who understand both the science and the stakes.

The Ask & Use of Funds

Immunomatics intends to raise $500,000 in this offering as a Simple Agreement for Future Equity (SAFE), with a 15% discount and a $12M post-money valuation cap. The proceeds will be allocated to four strategic areas:

FAQ


Overview